Skip to main content
. 2013 Sep 24;65(10):1666–1673. doi: 10.1002/acr.22044

Figure 1.

Figure 1

Proportions of patients achieving a clinically meaningful change from baseline in Health Assessment Questionnaire (HAQ) disability index (DI; ≥0.30) and 36-item Short Form health survey physical component summary (PCS; ≥5) and mental component summary (MCS; ≥5) scores at weeks 14, 24, 52, and 104. At weeks 52 and 104, all patients initially randomized to placebo were receiving golimumab (50 or 100 mg), and some patients initially randomized to golimumab 50 mg were receiving golimumab 100 mg.